sb 203580 has been researched along with alantolactone in 2 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (alantolactone) | Trials (alantolactone) | Recent Studies (post-2010) (alantolactone) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 127 | 0 | 96 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Clutter, MR; Crane, JM; Krutzik, PO; Nolan, GP | 1 |
| Ariyoshi, W; Hida, D; Knudson, CB; Knudson, W; Takahashi, N | 1 |
2 other study(ies) available for sb 203580 and alantolactone
| Article | Year |
|---|---|
High-content single-cell drug screening with phosphospecific flow cytometry.
Topics: Animals; Cell Line, Tumor; Drug Evaluation, Preclinical; Flow Cytometry; Humans; Janus Kinases; Mice; Mice, Inbred BALB C; Mitogen-Activated Protein Kinases; Phosphorus; Sensitivity and Specificity; Signal Transduction; STAT Transcription Factors | 2008 |
Mechanisms involved in enhancement of the expression and function of aggrecanases by hyaluronan oligosaccharides.
Topics: Aggrecans; Animals; Cartilage, Articular; Cattle; Cells, Cultured; Chondrocytes; Chromones; Collagen Type II; Drug Therapy, Combination; Endopeptidases; Flavonoids; Gene Expression Regulation, Enzymologic; Glucuronosyltransferase; Hyaluronan Receptors; Hyaluronic Acid; Imidazoles; Lactones; Morpholines; Oligosaccharides; Pyridines; Sesquiterpenes, Eudesmane; Signal Transduction; Viscosupplements | 2012 |